Table 1.
JME Patients n = 49 (%) |
|
---|---|
Age, y, mean ± SD | 27.6 ± 8.9 |
Gender, (Female: Male) | 25: 24 |
Family history of epilepsy | 7 (14.3) |
History of febrile seizures | 6 (12.2) |
Age of first seizure, y, mean ± SD | 14.2 ± 3.1 |
Seizure duration, y, mean ± SD | 13.4 ± 9.4 |
Age of diagnosis of epilepsy, y, mean ± SD | 16.2 ± 5.4 |
Age of diagnosis of JME, y, mean ± SD | 21.1 ± 8.7 |
Duration of follow up, y, mean ± SD | 11.4 ± 9.3 |
Year of delayed diagnosis of JME, y, mean ± SD | 6.9 ± 9.1 |
Seizure types | |
Myoclonic seizures only | 6 (12.2) |
Myoclonic + absence seizures | 2 (4.1) |
Myoclonic seizures + GTCS | 25 (51.0) |
Myoclonic + absence seizures + GTCS | 16 (32.7) |
First clinical manifestation | |
Myoclonic seizures | 18 (36.7) |
GTCS | 26 (53.1) |
Absence seizures | 5 (10.2) |
Timing of seizures | |
Awake only | 22 (44.9) |
Sleep only | 14 (28.6) |
Both awake and sleep | 13 (26.5) |
Seizure precipitant factors | |
Sleep deprivation | 10 (20.4) |
Flicking light | 8 (16.3) |
Soundsensitive | 3 (6.1) |
Stress | 7 (14.3) |
Fatigue | 2 (4.1) |
Common cold | 2 (4.1) |
Alcohol intake | 1 (2.0) |
Exercise | 1 (2.0) |
EEG features | |
Focal EEG discharges | 4 (8.2) |
Epileptiform discharges in the last EEG | 30 (61.2) |
No. of ASM tried, mean ± SD Current ASM treatment (range, 0–4) |
3.0 ± 1.9 (range, 1–10) |
No ASM | 1 (2.0) |
Monotherapy | 27 (55.1) |
Two ASMs | 14 (28.6) |
Three ASMs | 4 (8.2) |
Four ASMs | 3 (6.1) |
Most common ASM type | |
Levetiracetam | 34 (69.4) |
Valproic acid | 17 (34.7) |
Clonazepam | 14 (28.6) |
Seizure-free duration | |
>1 year | 24 (49.0) |
>6 months | 27 (55.1) |
>3 months | 30 (61.2) |
JME, juvenile myoclonic epilepsy; GTCS, generalized tonic-clonic seizures; EEG, electroencephalogram; ASM, antiseizure medication.